OLEMA PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $55.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $55.00K.
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $896.00K.
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $896.00K, a 201.68% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $297.00K, a 90.58% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $55.00K 10-Q · filed 2026-08-10 | $55.00K derived: sum of 3 quarters · filed 2026-08-10 | $55.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $55.00K 10-Q · filed 2026-05-12 | $55.00K derived: sum of 2 quarters · filed 2026-05-12 | $55.00K derived: sum of 3 quarters · filed 2026-05-12 | $951.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $896.00K derived: sum of 3 quarters · filed 2026-08-10 | $896.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $896.00K derived: sum of 2 quarters · filed 2026-08-10 | $896.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $896.00K 10-Q · filed 2026-08-10 | $896.00K 10-Q · filed 2026-08-10 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $896.00K derived: sum of 2 quarters · filed 2025-03-18 | $896.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $896.00K 10-Q · filed 2024-11-12 | $896.00K 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $297.00K derived: sum of 3 quarters · filed 2024-03-11 | $297.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $297.00K derived: sum of 2 quarters · filed 2022-11-08 | $297.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $297.00K 10-Q · filed 2022-08-09 | $297.00K 10-Q · filed 2022-08-09 | ||
| 2021-12-31 | $3.15M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |